Nanomedicine can be accumulated at tumor site by enhanced permeability and retention time (EPR) effect, and thus is used in various clinical trials in the form of nano-formulation even in cancer immunotherapy. Among various materials, hyaluronic acid (HA) has drawn tremendous attention owing to its superior biocompatibility and bio-degradability. Furthermore, it can actively target tumor because of CD 44 receptor, as it has specific binding affinity with HA, which is over expressed on the surface of cancer cell followed by receptor-mediated endocytosis. Therefore, it might have great potential as an effective cancer therapeutic delivering formulation.
Theoretically, for being an effective cancer immunotherapeutic agent, three elements are vitally required: foreign antigen, immunologic adjuvant, and delivery technology. According to the backgrounds of this research as I mentioned so far, if that ideal agent can be formulated, it would be an innovative cancer immunotherapeutic agent, which could overcome the limitations of conventional